| Name: | Atorvastatin Calcium Impurity-J |
| Catalogue No. | VE006263 |
| CAS No. | N/A |
| Description | Atorvastatin Calcium Impurity-J(CAS No: N/A) or (2E,5S)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-5-hydroxyhept-2-enoic acid is an impurity of Atorvastatin. it is a is highly plasma protein bound (over 98%) and has a volume of distribution of about 380 liters and is rapidly absorbed after oral administration with a peak plasma concentration at 1 to 2 hours. The bioavailability is low at 14% due to extensive first-pass metabolism. |
| References | McIver, Lindsey A., and Momin S. Siddique. “Atorvastatin.” Nih.gov, StatPearls Publishing, 5 Jan. 2019, www.ncbi.nlm.nih.gov/books/NBK430779/. Ramkumar, Satish, et al. “Statin Therapy: Review of Safety and Potential Side Effects.” Acta Cardiologica Sinica, vol. 32, no. 6, Taiwan Society of Cardiology, 2016, pp. 631–39, https://doi.org/10.6515/ACS20160611A. |
